AbbVie’s Rinvoq Vitiligo Data Set Up Q4 FDA Catalyst for ABBV Investors
Rinvoq’s promising vitiligo results and expected Q4 2026 FDA decision add a potential growth catalyst, though dividend concerns remain.
Wave Life Sciences Shares Rise as FDA Confirms Registrational Pathway for WVE-006
FDA alignment on WVE-006 trial design gives Wave Life Sciences a clearer regulatory path, but execution and clinical validation remain ahead.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
Q32 Bio Stock Falls 13.2% as Oppenheimer Stands by Rating Despite Trial-Data Concerns
Q32 Bio sharply underperformed biotech peers as investors questioned bempikibart efficacy, while Oppenheimer pointed to …
PolyPid Regains European Rights to D-PLEX100: What It Means for PYPD’s Strategy
PolyPid’s return of European rights to D-PLEX100 may expand partnership options and reshape the valuation narrative for …
Outlook Therapeutics Seeks CMS Reimbursement Code Ahead of LYTENAVA Launch
Outlook Therapeutics’ CMS reimbursement application marks a key commercial milestone for LYTENAVA and $OTLK ahead of its…
Merck’s Positive Phase 2 HS Data Offer a Glimpse Beyond Oncology
Merck’s positive Phase 2 hidradenitis suppurativa data could broaden investor focus beyond its oncology franchise.
Praxis Precision Medicine Options Activity Builds Ahead of Two FDA Decisions
Praxis Precision Medicine is seeing elevated options activity as traders position around two FDA decisions, analyst targ…
Connect Biopharma Shares Jump 25% on Positive Phase 2 COPD Data
Connect Biopharma shares jumped 25% after positive Phase 2 COPD data for rademikibart, putting biotech catalyst volatili…
Kodiak Sciences Nearly Triples to $90: Can a $5.64 Billion Valuation Hold?
Kodiak Sciences’ jump from roughly $32 to $90 creates a sharp clash between biotech momentum and the company’s funding r…
Eli Lilly Builds Q4 Momentum With Positive Ebglyss Phase 3b Results
Positive Ebglyss and retatrutide trial updates give Eli Lilly’s pipeline broader support heading into Q4.
Capricor Therapeutics Jumps 12.8% as Analysts Raise Stakes Ahead of FDA Decision
CAPR traded 12.84% higher after B. Riley upgraded the stock to Buy, sharpening focus on deramiocel and its upcoming FDA …